Literature DB >> 21729181

Mechanisms of immunotherapy to wasp and bee venom.

C Ozdemir1, U C Kucuksezer, M Akdis, C A Akdis.   

Abstract

Hymenoptera venoms are important allergens that can elicit both local and systemic allergic reactions, including life-threatening anaphylaxis. Venom immunotherapy (VIT) remains the most effective treatment, reducing the risk of systemic reactions in individuals with Hymenoptera venom allergy. VIT can restore normal immunity against venom allergens and provide patients with a lifetime of tolerance to venoms. During VIT, peripheral tolerance is induced by the generation of allergen-specific regulatory T (Treg) cells, which suppress proliferative and cytokine responses against the venom allergens. Treg cells are characterized by IL-10 secretion that directly or indirectly influence effector cells of allergic inflammation, such as mast cells, basophils and eosinophils. Treg cells also have influence on B cells, suppressing IgE production and inducing the production of blocking type IgG4 antibodies against venom allergens. An accumulating body of evidence suggests that Treg cells may affect allergen sensitization and methods for enhancing this cell population may eventually improve the efficacy of VIT. In this article, immune mechanisms enrolled in bee and wasp VIT are reviewed.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21729181     DOI: 10.1111/j.1365-2222.2011.03812.x

Source DB:  PubMed          Journal:  Clin Exp Allergy        ISSN: 0954-7894            Impact factor:   5.018


  34 in total

Review 1.  Mechanisms and assessment of IgG4-related disease: lessons for the rheumatologist.

Authors:  Motohisa Yamamoto; Hiroki Takahashi; Yasuhisa Shinomura
Journal:  Nat Rev Rheumatol       Date:  2013-12-03       Impact factor: 20.543

Review 2.  Mast Cells and IgE can Enhance Survival During Innate and Acquired Host Responses to Venoms.

Authors:  Stephen J Galli; Philipp Starkl; Thomas Marichal; Mindy Tsai
Journal:  Trans Am Clin Climatol Assoc       Date:  2017

Review 3.  Treating human autoimmunity: current practice and future prospects.

Authors:  Michael D Rosenblum; Iris K Gratz; Jonathan S Paw; Abul K Abbas
Journal:  Sci Transl Med       Date:  2012-03-14       Impact factor: 17.956

4.  Mast cells and IgE in defense against lethality of venoms: Possible "benefit" of allergy[].

Authors:  Stephen J Galli; Martin Metz; Philipp Starkl; Thomas Marichal; Mindy Tsai
Journal:  Allergo J Int       Date:  2020-03-02

Review 5.  Immunology of Bee Venom.

Authors:  Daniel Elieh Ali Komi; Farzaneh Shafaghat; Ricardo D Zwiener
Journal:  Clin Rev Allergy Immunol       Date:  2018-06       Impact factor: 8.667

6.  Type B CpG oligodeoxynucleotides induce Th1 responses to peanut antigens: modulation of sensitization and utility in a truncated immunotherapy regimen in mice.

Authors:  Mike Kulis; Balachandra Gorentla; A Wesley Burks; Xiao-Ping Zhong
Journal:  Mol Nutr Food Res       Date:  2013-02-05       Impact factor: 5.914

7.  Bee venom phospholipase A2 induces a primary type 2 response that is dependent on the receptor ST2 and confers protective immunity.

Authors:  Noah W Palm; Rachel K Rosenstein; Shuang Yu; Dominik D Schenten; Esther Florsheim; Ruslan Medzhitov
Journal:  Immunity       Date:  2013-10-24       Impact factor: 31.745

Review 8.  The Mast Cell-IgE Paradox: From Homeostasis to Anaphylaxis.

Authors:  Stephen J Galli
Journal:  Am J Pathol       Date:  2016-02       Impact factor: 4.307

9.  IgE antibodies, FcεRIα, and IgE-mediated local anaphylaxis can limit snake venom toxicity.

Authors:  Philipp Starkl; Thomas Marichal; Nicolas Gaudenzio; Laurent Lionel Reber; Riccardo Sibilano; Mindy Tsai; Stephen Joseph Galli
Journal:  J Allergy Clin Immunol       Date:  2015-09-26       Impact factor: 10.793

Review 10.  Testing the 'toxin hypothesis of allergy': mast cells, IgE, and innate and acquired immune responses to venoms.

Authors:  Mindy Tsai; Philipp Starkl; Thomas Marichal; Stephen J Galli
Journal:  Curr Opin Immunol       Date:  2015-07-23       Impact factor: 7.486

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.